AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24165282
Drug: Intrathecal baclofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal baclofen treatment
Trial: 18210310
Drug: Anesthetic cream
RxNorm normalized name: DIBUCAINE/DIPERODON ANESTHETIC CREAM
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthetic cream (lidocaine/prilocaine) applied prior to galactography in Group B (27 patients)
Trial: 18210310
Drug: No anesthetic
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anesthetic cream in Group A (19 patients)
Trial: 8660042
Drug: D-penicillamine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-penicillamine treatment
Trial: 1819153
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg frusemide
Trial: 6345111
Drug: Liquid antacid
RxNorm normalized name: GNP Liquid Antacid Maximum Strength 400mg-400mg-40mg/5ml Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid antacid (Maalox Therapeutic Concentration, 15 ml, 80 mEq, taken 7 times daily)
Trial: 6345111
Drug: Placebo (taken
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (taken 7 times daily)
Trial: 30126028
Drug: High-dose peanut
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose peanut OIT (3000 mg)
Trial: 30126028
Drug: Low-dose peanut
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose peanut OIT (300 mg)
Trial: 29098683
Drug: Sufentanil (target‐controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil (target‐controlled infusion, effect‐site concentration of 0.3 ng.ml‐1)
Trial: 9733365
Drug: Moxonidine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine (0.4 mg/day; 1 month)
Trial: 29726939
Drug: Ustekinumab 130
RxNorm normalized name: ustekinumab 130 MG in 26 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab 130 mg
Trial: 29726939
Drug: Ustekinumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab (all doses)
Trial: 19725852
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MR presence and viability in the region of the pacing lead
Trial: 18727339
Drug: Warm compresses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm compresses applied to the injection site before self-injection
Trial: 18727339
Drug: Usual methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual methods of injection preparation
Trial: 21623649
Drug: Vitamin B12
RxNorm normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B12 injections
Trial: 6299982
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg terbutaline subcutaneously
Trial: 6299982
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg terbutaline orally
Trial: 31864383
Drug: Generic G-CBT
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generic G-CBT program for anxiety disorders
Trial: 23754205
Drug: Metronidazole gel
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole gel (3% w/v)
Trial: 23754205
Drug: Metronidazole solution
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole solution (0.5% w/v)
Trial: 22226343
Drug: Inhaled loxapine
RxNorm normalized name: loxapine Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled loxapine 5 mg (bipolar disorder)
Trial: 22226343
Drug: Inhaled loxapine
RxNorm normalized name: loxapine Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled loxapine 10 mg (bipolar disorder)
Trial: 12405366
Drug: Intrathecal drug
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal drug therapy (IDT)
Trial: 12405366
Drug: Conventional pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional pain therapy (CPT)
Trial: 7840079
Drug: Biotin supplementation
RxNorm normalized name: Biotin
DrugBank: Biotin (DB00121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biotin supplementation (10 mg/d)
Trial: 29996800
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 1.5 g daily in two divided doses
Trial: 29996800
Drug: Cyclophosphamide (CYC)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (CYC) given intravenously as a monthly pulse
Trial: 20442386
Drug: Azithromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (250 mg for weight 18-35.9 kg or 500 mg for weight >= 36 kg) 3 days per week for 168 days
Trial: 19406291
Drug: Sertraline (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (daily oral doses starting at 25mg, increasing to therapeutic levels up to 200mg)
Trial: 19406291
Drug: Sertraline and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline and Placebo (both groups)
Trial: 16586190
Drug: Gabapentin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (300 mg to 3,600 mg)
Trial: 11311964
Drug: Gliclazide (80-240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide (80-240 mg)
Trial: 11311964
Drug: Glibenclamide (5-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (5-15 mg)
Trial: 8985076
Drug: Combined regional/general
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined regional/general anesthesia with intraoperative epidural catheter anesthesia using Bupivacaine and postoperative epidural morphine
Trial: 8985076
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia with postoperative patient-controlled intravenous morphine
Trial: 8501777
Drug: Orange juice
RxNorm normalized name: Orange juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orange juice (1.2 l. per day, containing 60 mEq. potassium and 190 mEq. citrate)
Trial: 3630312
Drug: sublingual nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sublingual nifedipine 20 mg
Trial: 3630312
Drug: intravenous nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous nifedipine 1 mg
Trial: 27233239
Drug: Vernakalant (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vernakalant (3 mg/kg infusion over 10 min, followed by 2 mg/kg if AF not terminated)
Trial: 25280032
Drug: Pidotimod treatment
RxNorm normalized name: pidotimod
DrugBank: Pidotimod (DB11364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pidotimod treatment for 30 days
Trial: 17369518
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving task-specific therapy alone
Trial: 9988543
Drug: Estrogen receptor
RxNorm normalized name: Estrogen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen receptor status positive
Trial: 9988543
Drug: Progesterone receptor
RxNorm normalized name: Progesterone receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone receptor status positive
Trial: 7859244
Drug: Quinapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (10 mg QD to 20 mg QD, titrated based on blood pressure response)
Trial: 7859244
Drug: Quinapril (part
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (part of antihypertensive regimen)
Trial: 28879792
Drug: Naproxen (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (750 mg)
Trial: 22088520
Drug: Tirofiban with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirofiban with unfractionated heparin (UFH)
Trial: 18157558
Drug: 10% Isomalt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% Isomalt solutions rinsed for 5 minutes daily
Trial: 18157558
Drug: 10% Isomalt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% Isomalt additions to re- or demineralizing solutions
Trial: 18157558
Drug: 10% Isomalt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% Isomalt containing toothpaste brushed three times daily
Trial: 12588772
Drug: Rosiglitazone 4
RxNorm normalized name: rosiglitazone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 4 mg (twice daily)
Trial: 8720318
Drug: Erythromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (500 mg t.i.d. over 5 days)
Trial: 8720318
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg o.d. over 3 days)
Trial: 1770275
Drug: Gonadotropin releasing
RxNorm normalized name: Gonadotropin releasing factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropin releasing hormone agonist (GNRHa), Buserelin, prior to and during induction of ovulation by hMG (Group I‐‐long protocol)
Trial: 16189630
Drug: Kremezin (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kremezin (oral carbonaceous adsorbent) paired with conventional treatment (antihypertensive therapy and low-protein diet)
Trial: 16189630
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (antihypertensive therapy and low-protein diet) alone
Trial: 12202465
Drug: Alendronate (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (5 mg or more)
Trial: 12202465
Drug: Alendronate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (10 mg or more)
Trial: 12202465
Drug: Alendronate (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (5 mg or greater)
Trial: 9036798
Drug: Low-dose cidofovir
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cidofovir (5 mg/kg once weekly for 2 weeks, then 3 mg/kg once every 2 weeks)
Trial: 9036798
Drug: High-dose cidofovir
RxNorm normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose cidofovir (5 mg/kg once weekly for 2 weeks, then 5 mg/kg once every 2 weeks)
Trial: 9036798
Drug: Deferral group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferral group (treatment deferred until retinitis progressed)
Trial: 9036798
Drug: Low-dose cidofovir
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cidofovir group
Trial: 9036798
Drug: High-dose cidofovir
RxNorm normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose cidofovir group
Trial: 27558098
Drug: Ponesimod regimen
RxNorm normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ponesimod regimen A (incremental dose increase from 2 to 20 mg in 9 steps)
Trial: 27558098
Drug: Ponesimod regimen
RxNorm normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ponesimod regimen B (10 mg for 7 days followed by a single-dose administration of 20 mg)
Trial: 17124721
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg DiaPep277
Trial: 17124721
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg mannitol (placebo)
Trial: 14727273
Drug: 1.5 mL
RxNorm normalized name: Humulin 70/30 1.5 ML Pen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mL hyperbaric bupivacaine 0.5% (7.5 mg)
Trial: 14727273
Drug: 4.2 mL
RxNorm normalized name: ISOPROPYL ALCOHOL 4.2 mL TOPICAL CLOTH [ISOPROPYL ALCOHOL WIPES]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.2 mL hypobaric bupivacaine 0.18% (7.5 mg)
Trial: 11771827
Drug: Insulin, glucose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin, glucose, and potassium (GIK) infusion using an euglycemic clamp technique.
Trial: 11771827
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no GIK infusion).
Trial: 9316182
Drug: ACTH 4‐10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACTH 4‐10 (1.25 mg intravenously, 30 minutes before testing)
Trial: 2961815
Drug: HBIg (0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBIg (0.06 ml/kg) administered intramuscularly within 3 days after exposure, followed by a second dose 1 month later.
Trial: 2961815
Drug: HBIg (0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBIg (0.06 ml/kg) administered within 3 days followed by HB vaccine (HEVAC‐B Pasteur 10 micrograms) within 7 days after exposure.
Trial: 2681882
Drug: L 841
RxNorm normalized name: WITCH HAZEL 841 mg in 1 mL TOPICAL LIQUID [Witch Hazel]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L 841 A (vincristine + prednisone for remission induction, 18 Gy cranial irradiation + intrathecal methotrexate for CNS leukemia prophylaxis, maintenance with MTX iv alternating 5-day course of VCR + PDN + 6-mercaptopurine)
Trial: 2681882
Drug: L 841
RxNorm normalized name: WITCH HAZEL 841 mg in 1 mL TOPICAL LIQUID [Witch Hazel]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L 841 B (asparaginase added)
Trial: 2681882
Drug: I 841
RxNorm normalized name: I 123
DrugBank: Iodide I-123 (DB09420)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I 841 C (asparaginase, Adriamycin, high-dose MTX 100 mg/kg)
Trial: 24229823
Drug: Montelukast 4
RxNorm normalized name: montelukast 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 4 to 5 mg once daily
Trial: 19826135
Drug: Elesclomol 213
RxNorm normalized name: Élesclomol
DrugBank: Elesclomol (DB05719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elesclomol 213 mg/m² plus paclitaxel 80 mg/m² (E + P)
Trial: 19826135
Drug: Paclitaxel 80
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 80 mg/m² alone
Trial: 16731214
Drug: Nortriptyline, fluoxetine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline, fluoxetine, or placebo (double-blind methodology)
Trial: 16731214
Drug: Antidepressant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant treatment (nortriptyline or fluoxetine)
Trial: 9525302
Drug: smoking intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: smoking intervention plus bronchodilator
Trial: 3611686
Drug: Milk tolerance
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk tolerance test (500 ml milk)
Trial: 29150845
Drug: Sorbitol 3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorbitol 3.2 g
Trial: 29150845
Drug: Sorbitol 10.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorbitol 10.2 g
Trial: 29150845
Drug: Sorbitol 13.4
RxNorm normalized name: docusate sodium 10 MG / sorbitol 13.4 GM Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorbitol 13.4 g
Trial: 29150845
Drug: Lamivudine 300
RxNorm normalized name: lamivudine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 300 mg alone
Trial: 22112014
Drug: Pimecrolimus 1%
RxNorm normalized name: PIMECROLIMUS 1% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimecrolimus 1% cream (subgroup analysis)
Trial: 22112014
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream (subgroup analysis)
Trial: 20403940
Drug: Lactobacillus GG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus GG (LGG) at a dose of 10^9 colony-forming units in 100 mL of a fermented milk product (LGG group, n = 376)
Trial: 17555526
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of antiepileptic drugs (CBZ)
Trial: 14624771
Drug: r‐hGH 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐hGH 0.05 mg/kg/day (high dose)
Trial: 14624771
Drug: r‐hGH 0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐hGH 0.025 mg/kg/day (low dose)
Trial: 7719072
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with prednisolone 1% eyedrops
Trial: 7719072
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with indomethacin 1% eyedrops
Trial: 7719072
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with prednisolone 1% + indomethacin 1% eyedrops
Trial: 2043017
Drug: Pilocarpine hydrochloride
RxNorm normalized name: Pilocarpine Hydrochloride
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pilocarpine hydrochloride (5-mg capsules, three times daily for 5 months)
Trial: 6167116
Drug: 5% benzoyl
RxNorm normalized name: BENZOYL PEROXIDE 2.5 g in 100 mL TOPICAL SOAP [Benzoyl Acne Wash -2.5% Benzoyl Peroxide]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% benzoyl peroxide preparation
Trial: 30861337
Drug: GSK3389404 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3389404 (10 mg, 30 mg, 60 mg, 120 mg single doses)
Trial: 30861337
Drug: GSK3389404 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3389404 (30 mg, 60 mg, 120 mg multiple doses, once weekly for 4 weeks)
Trial: 19395585
Drug: Dasatinib 50
RxNorm normalized name: dasatinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib 50 mg alone
Trial: 19395585
Drug: Famotidine 40
RxNorm normalized name: famotidine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 40 mg given 10 hours before dasatinib
Trial: 19395585
Drug: Antacid (Maalox)
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antacid (Maalox) 2 hours before dasatinib
Trial: 19395585
Drug: Antacid (Maalox)
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antacid (Maalox) coadministered with dasatinib
Trial: 17224718
Drug: Modafinil (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (400 mg daily)
Trial: 15131729
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application using a body wash containing 0.15% vitamin E and 0.10% vitamin E acetate
Trial: 11669085
Drug: Mistletoe preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mistletoe preparation (Abnobaviscum Quercus) injected subcutaneously three times a week for 6 months
Trial: 11669085
Drug: Pre-treatment observation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment observation for 6 months
Trial: 9536925
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic peptide infusion (0.01 microgram min-1 kg-1)
Trial: 795433
Drug: Diflucortolone valerate
RxNorm normalized name: diflucortolone valerate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflucortolone valerate cream and ointment (0.1%)
Trial: 795433
Drug: Diflucortolone valerate
RxNorm normalized name: diflucortolone valerate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflucortolone valerate fatty ointment (0.1%)
Trial: 25975558
Drug: Inosine tablets
DrugBank: Inosine (DB04335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inosine tablets and vitamin C (Control)
Trial: 23815742
Drug: Benidipine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benidipine (2 mg daily, increased to 8 mg daily)
Trial: 23815742
Drug: Amlodipine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (2.5 mg daily, increased to 10 mg daily)
Trial: 21528596
Drug: Calcichew D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcichew D3 tablets and acupoint catgut embedding
Trial: 21528596
Drug: Calcichew D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcichew D3 tablets (oral administration)
Trial: 21528596
Drug: Calcichew D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcichew D3 tablets and Xianling Gubao capsule (oral administration)
Trial: 16845799
Drug: Continuously slow
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuously slow intravenous arsenic trioxide (As2O3) infusion regimen for 24 hours at an infusion rate of 8 drips per minute, total infusion duration of about 18-21 hours daily, daily dosage of 0.16 mg/kg
Trial: 16845799
Drug: Routine regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine regimen with arsenic trioxide (As2O3) infusion at an infusion rate of 45-55 drips per minute, total infusion duration of about 2-3 hours daily, daily dosage of 0.16 mg/kg
Trial: 16845799
Drug: Continuously slow
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuously slow intravenous arsenic trioxide (As2O3) infusion regimen
Trial: 16845799
Drug: Routine regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine regimen with arsenic trioxide (As2O3) infusion
Trial: 14665897
Drug: Concomitant use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant use of sildenafil (100 mg) and a vacuum entrapment device (VED)
Trial: 9053968
Drug: Indomethacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (100 mg intravenously)